Dengue is the most common vector-borne viral disease, causing nearly 400 million
infections yearly. Currently there are no approved therapies. Antibody epitopes that elicit …

Dengue virus is the most globally prevalent mosquito-transmitted virus. Primary infection
with one of four cocirculating serotypes (DENV-1 to-4) causes a febrile illness, but …

We recently described our most potently neutralizing monoclonal antibody, E106, which
protected against lethal Dengue virus type 1 (DENV-1) infection in mice. To further …

Eliciting broadly neutralizing antibodies (bNAbs) against the four dengue virus serotypes
(DENV1-4) that are spreading into new territories is an important goal of vaccine design. To …

Affinity improvement of proteins, including antibodies, by computational chemistry broadly
relies on physics-based energy functions coupled with refinement. However, achieving …

Background Dengue virus (DENV) is a significant public health threat in tropical and
subtropical regions of the world. A therapeutic antibody against the viral envelope (E) …

Dengue virus (DENV) is the most prevalent insect-transmitted viral disease in humans
globally, and currently no specific therapy or vaccine is available. Protection against DENV …

Dengue virus (DENV) is a worldwide health burden, and a safe vaccine is needed.
Neutralizing antibodies bind to quaternary epitopes on DENV envelope (E) protein …

A therapy for dengue is still elusive. We describe the neutralizing and protective capacity of
a dengue serotype-cross-reactive antibody isolated from the plasmablasts of a patient …

Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV)
for which there are no safe, effective drugs approved for clinical use. Here, by using …